VCANBIO CELL & GENE ENGINEERING CORP., LTD

Vcanbio Cell & Gene Engineering Corp., Ltd

600645

CNE000000545

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 16/07/2024 BST			5-day change	1st Jan Change
16.26 ^CNY	+1.12%		+2.07%	-19.78%

07-02	Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	CI
06-21	Vcanbio Cell & Gene Engineering's Unit Gets Nod to Trial Stem Cell Drug	MT

Zhongyuan Union Stem Cell Bioengineering Co., Ltd.(SHSE:600645) added to Shanghai Stock Exchange Health Care Sector Index

January 08, 2013 at 05:00 am

Zhongyuan Union Stem Cell Bioengineering Co., Ltd. will be added to the Shanghai Stock Exchange Health Care Sector Index

Latest news about Vcanbio Cell & Gene Engineering Corp., Ltd

Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	07-01	CI
Vcanbio Cell & Gene Engineering's Unit Gets Nod to Trial Stem Cell Drug	06-21	MT
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback announced on February 19, 2024, has closed with 6,181,212 shares, representing 1.32% for CLP 100 million.	04-17	CI
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	04-01	CI
Vcanbio Cell & Gene Engineering Corp., Ltd announces an Equity Buyback for CLP 200 million worth of its shares.	02-19	CI
Vcanbio Cell & Gene Engineering Corp., Ltd authorizes a Buyback Plan	02-16	CI
Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it has received CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd	12-25	CI
Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd	11-07	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
Vcanbio Cell & Gene Gets Greenlight to Trial COVID-19 Drug	16/10/23	MT
Vcanbio Cell & Gene Engineering Corp., Ltd agreed to acquire additional 3% stake in Heyuan Biological Technology Co., Ltd. from Beijing Fuyuan Zhiyuan Biotechnology Partnership (Limited Partnership).	28/09/23	CI
Vcanbio Cell & Gene Engineering Corp., Ltd(XSSC:600645) added to S&P Global BMI Index	18/09/23	CI
MET Group signs energy supply deal with Commonwealth LNG	04/09/23	RE
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
Vcanbio Cell & Gene’s Pulmonary Fibrosis Treatment Wins Orphan Drug Designation in US	14/08/23	MT
Vcanbio Cell & Gene Unit Gets Nod to Begin Clinical Trial of Respiratory Distress Medication	08/06/23	MT
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	25/04/23	CI
Vcanbio Cell & Gene Engineering Wins Nod to Trial Stem Cell Therapy For Liver Cirrhosis	13/02/23	MT
C-Mer Eye Care Raises HK$116.1 Million in Share Subscription Deal	09/12/22	MT
C-Mer Eye Care To Issue More Than 30 Million New Shares to Vcanbio Cell Chairman	05/12/22	MT
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI

Chart Vcanbio Cell & Gene Engineering Corp., Ltd

Duration

Period

Chart Vcanbio Cell & Gene Engineering Corp., Ltd

More charts

VCANBIO CELL & GENE ENGINEERING CORP., LTD is a China-based company, principally engaged in the preparation, detection and storage of cells. The Company is also engaged in cell culture and gene detection and storage, as well as the production and sale of cytokines culture solutions, cosmetics and detection reagents. The Company conducts its businesses mainly within domestic markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

29/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
VCANBIO CELL & GENE ENGINEERING CORP., LTD	-19.78%	1.02B
BIOMÉRIEUX	-6.61%	12.07B
LANTHEUS HOLDINGS, INC.	+96.15%	8.2B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-18.38%	6.59B
DIASORIN S.P.A.	+9.13%	5.89B
AUTOBIO DIAGNOSTICS CO., LTD.	-21.66%	3.47B
ANDON HEALTH CO., LTD.	+5.36%	2.52B
MYRIAD GENETICS, INC.	+41.54%	2.48B
VITROLIFE AB	+17.72%	2.3B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-18.43%	1.58B